230 related articles for article (PubMed ID: 21652078)
1. Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences.
Ditta LC; Shildkrot Y; Wilson MW
Ophthalmology; 2011 Sep; 118(9):1754-9. PubMed ID: 21652078
[TBL] [Abstract][Full Text] [Related]
2. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations.
Demirci H; McCormick SA; Finger PT
Arch Ophthalmol; 2000 Jul; 118(7):885-91. PubMed ID: 10900099
[TBL] [Abstract][Full Text] [Related]
3. Limbal stem cell deficiency after topical mitomycin C therapy for primary acquired melanosis with atypia.
Lichtinger A; Pe'er J; Frucht-Pery J; Solomon A
Ophthalmology; 2010 Mar; 117(3):431-7. PubMed ID: 20060167
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of 9 squamous epithelial carcinoma in situ lesions of the conjunctiva (CIN) with mitomycin C eyedrops in cytological and DNA image cytometric control].
Cartsburg O; Kersten A; Sundmacher R; Nadjari B; Pomjanski N; Böcking A
Klin Monbl Augenheilkd; 2001 Jun; 218(6):429-34. PubMed ID: 11488009
[TBL] [Abstract][Full Text] [Related]
5. Treatment of ocular surface squamous neoplasia with Mitomycin C.
Gupta A; Muecke J
Br J Ophthalmol; 2010 May; 94(5):555-8. PubMed ID: 20447963
[TBL] [Abstract][Full Text] [Related]
6. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience.
Kurli M; Finger PT
Graefes Arch Clin Exp Ophthalmol; 2005 Nov; 243(11):1108-14. PubMed ID: 15940485
[TBL] [Abstract][Full Text] [Related]
7. Topical mitomycin C for the treatment of conjunctival tumor.
Ozcan AA; Sizmaz S; Yagmur M
Ophthalmologica; 2007; 221(1):14-7. PubMed ID: 17183195
[TBL] [Abstract][Full Text] [Related]
8. Postoperative topical mitomycin C in conjunctival squamous cell neoplasia.
Akpek EK; Ertoy D; Kalayci D; Hasiripi H
Cornea; 1999 Jan; 18(1):59-62. PubMed ID: 9894938
[TBL] [Abstract][Full Text] [Related]
9. Limbal stem cell deficiency following topical mitomycin C treatment of conjunctival-corneal intraepithelial neoplasia.
Dudney BW; Malecha MA
Am J Ophthalmol; 2004 May; 137(5):950-1. PubMed ID: 15126170
[TBL] [Abstract][Full Text] [Related]
10. [Mitomycin C in treatment of conjunctival melanoma and primary acquired melanosis].
Werschnik C; Lommatzsch PK
Klin Monbl Augenheilkd; 1998 Jun; 212(6):465-8. PubMed ID: 9715467
[TBL] [Abstract][Full Text] [Related]
11. The treatment of primary acquired melanosis (PAM) with atypia by topical Mitomycin C.
Pe'er J; Frucht-Pery J
Am J Ophthalmol; 2005 Feb; 139(2):229-34. PubMed ID: 15733981
[TBL] [Abstract][Full Text] [Related]
12. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications.
Russell HC; Chadha V; Lockington D; Kemp EG
Br J Ophthalmol; 2010 Oct; 94(10):1316-21. PubMed ID: 20530655
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of topical mitomycin C 0.02% for primary and recurrent conjunctival-corneal intraepithelial neoplasia.
Ballalai PL; Erwenne CM; Martins MC; Lowen MS; Barros JN
Ophthalmic Plast Reconstr Surg; 2009; 25(4):296-9. PubMed ID: 19617789
[TBL] [Abstract][Full Text] [Related]
14. Management of diffuse ocular surface squamous neoplasia: efficacy and complications of topical chemotherapy.
Rudkin AK; Dempster L; Muecke JS
Clin Exp Ophthalmol; 2015; 43(1):20-5. PubMed ID: 24995542
[TBL] [Abstract][Full Text] [Related]
15. Cytologic changes in the conjunctiva mimicking malignancy after topical mitomycin C chemotherapy.
Salomão DR; Mathers WD; Sutphin JE; Cuevas K; Folberg R
Ophthalmology; 1999 Sep; 106(9):1756-60; discussion 1761. PubMed ID: 10485547
[TBL] [Abstract][Full Text] [Related]
16. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients.
Shields CL
Trans Am Ophthalmol Soc; 2000; 98():471-92. PubMed ID: 11190037
[TBL] [Abstract][Full Text] [Related]
17. Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma.
Prabhasawat P; Tarinvorakup P; Tesavibul N; Uiprasertkul M; Kosrirukvongs P; Booranapong W; Srivannaboon S
Cornea; 2005 May; 24(4):443-8. PubMed ID: 15829803
[TBL] [Abstract][Full Text] [Related]
18. Epiphora as a side effect of topical mitomycin C.
Kopp ED; Seregard S
Br J Ophthalmol; 2004 Nov; 88(11):1422-4. PubMed ID: 15489486
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
20. Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma.
Shields CL; Naseripour M; Shields JA
Am J Ophthalmol; 2002 May; 133(5):601-6. PubMed ID: 11992855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
